Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 1;44(2S):S158-S161.
doi: 10.1097/INF.0000000000004632. Epub 2025 Feb 14.

Protecting Against Respiratory Syncytial Virus: An Online Questionnaire Study Exploring UK Parents' Acceptability of Vaccination in Pregnancy or Monoclonal Antibody Administration for Infants

Simone Paulson  1   2 , Alasdair P S Munro  1   2 , Katrina Cathie  1   2 , Helen Bedford  3 , Christine E Jones  1   2
Affiliations

Protecting Against Respiratory Syncytial Virus: An Online Questionnaire Study Exploring UK Parents' Acceptability of Vaccination in Pregnancy or Monoclonal Antibody Administration for Infants

Simone Paulson et al. Pediatr Infect Dis J. .

Abstract

Background: Maternal vaccination and infant monoclonal antibodies are promising avenues to protect young infants from respiratory syncytial virus (RSV) infection. Successful inclusion into the UK immunization schedule depends on parental acceptability, among other factors.

Methods: An online cross-sectional survey from August to September 2023 exploring the likelihood of accepting, and preference for, either method of RSV prophylaxis, and reasons given for these. A questionnaire was distributed via social media networks to UK participants with a child under the age of 2 years and/or pregnant.

Results: A total of 1620 participants completed the survey. Participants' median age was 33 years [interquartile range (IQR), 31-36], 92% were of White ethnicity. Acceptability was high, but higher for a maternal vaccine than an infant monoclonal antibody (P < 0.0001). Concerns about safety, need for more information and number of vaccines given to infants already were common reasons for hesitancy. Lacking knowledge about RSV was associated with a lower likelihood of accepting either option [maternal vaccine: odds ratio (OR): 0.32, 95% confidence interval (CI): 0.16-0.68, P = 0.002; infant monoclonal antibody: OR: 0.35, 95% CI: 0.19-0.68, P = 0.002], as was identifying as Black, Black British, African or Caribbean ethnic group, or having declined the routinely recommended antenatal vaccines.

Conclusions: While most parents would accept a maternal vaccine or infant monoclonal antibody to protect their infant against RSV, understanding preferences, influencing factors and concerns is essential to optimize immunization programs. This study highlights the information parents require to make an informed choice about RSV protection.

PubMed Disclaimer

Conflict of interest statement

C.E.J. is a member of the executive board of the IMPRINT Network. She is the national coordinating investigator for a clinical trial of an investigational RSV vaccine on behalf of University Hospital Southampton, sponsored by Moderna, but has received no personal funding. She attended an advisory board for Sanofi where RSV prevention strategies were discussed and received personal funding for this. She is a member of the JCVI RSV subcommittee. S.P. and A.P.S.M. are subinvestigators for the HARMONIE clinical trial of nirsevimab, sponsored by Sanofi, but receive no personal funding. K.C. acts on behalf of University Hospital Southampton NHS Foundation Trust as an investigator and/or providing consultative advice on studies funded or sponsored by vaccine manufacturers including AstraZeneca, GlaxoSmithKline, Janssen, Medimmune, Merck, Pfizer, Sanofi, Iliad and Valneva. She receives no personal financial payment for this work. H.B. has no conflicts of interest to disclose.

References

    1. O’Brien KL, Baggett HC, Brooks WA, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394:757–779.
    1. Li Y, Wang X, Blau DM, et al.; Respiratory Virus Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047–2064.
    1. Modjarrad K, Giersing B, Kaslow DC, et al.; WHO RSV Vaccine Consultation Expert Group. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23-24 March 2015. Vaccine. 2016;34:190–197.
    1. Esposito S, Abu Raya B, Baraldi E, et al. RSV prevention in all infants: which is the most preferable strategy? Front Immunol. 2022;13(880368).
    1. MHRA. Final Decision Letter. Available at: https://cms.mhra.gov.uk/pip/mhra-100067-pip01-21-m01-update.2022 . Accessed April 2023.

MeSH terms

Substances

Grants and funding

LinkOut - more resources